|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
C4 Therapeutics, Inc. (CCCC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile C4 Therapeutics is a biopharmaceutical company engaged in the development of novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Co.'s primary product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,667 |
| Total Buy Value |
$0 |
$0 |
$0 |
$31,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Siegel Jolie |
Chief Legal Officer |
• – – |
2022-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
3,750 |
|
- |
|
| Crystal Adam |
Chief Medical Officer |
• – – |
2022-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
18,750 |
|
- |
|
| Schick Kelly |
Chief People Officer |
• – – |
2022-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
3,750 |
|
- |
|
| Fisher Stewart |
Chief Scientific Officer |
• – – |
2022-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
75,140 |
|
- |
|
| Fisher Stewart |
Chief Scientific Officer |
• – – |
2022-04-12 |
4 |
OE |
$3.71 |
$137,120 |
D/D |
28,084 |
71,390 |
|
- |
|
| Hirsch Andrew |
President & CEO |
• • – |
2022-04-12 |
4 |
B |
$8.40 |
$84,000 |
D/D |
10,000 |
10,000 |
2.81 |
- |
|
| Dubin Glenn |
Director |
– • – |
2022-04-04 |
4 |
A |
$26.46 |
$10,028 |
D/D |
379 |
873 |
|
- |
|
| Cohen Alain J |
Director |
– • – |
2022-04-04 |
4 |
A |
$26.46 |
$10,266 |
D/D |
388 |
928 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2022-04-04 |
4 |
A |
$26.46 |
$9,023 |
D/D |
341 |
88,316 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2022-01-26 |
4 |
OE |
$2.11 |
$8,338 |
D/D |
2,137 |
87,975 |
|
- |
|
| Dubin Glenn |
Director |
– • – |
2022-01-04 |
4 |
A |
$31.58 |
$6,284 |
D/D |
199 |
494 |
|
- |
|
| Cohen Marc A |
Director |
– • – |
2022-01-04 |
4 |
A |
$31.58 |
$20,748 |
D/D |
657 |
1,118 |
|
- |
|
| Salter Malcolm |
Director |
– • – |
2022-01-04 |
4 |
A |
$31.58 |
$13,516 |
D/D |
428 |
11,380 |
|
- |
|
| Cohen Alain J |
Director |
– • – |
2022-01-04 |
4 |
A |
$31.58 |
$10,042 |
D/D |
318 |
540 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2022-01-04 |
4 |
A |
$31.58 |
$8,779 |
D/D |
278 |
85,838 |
|
- |
|
| Crystal Adam |
Chief Medical Officer |
• – – |
2022-01-04 |
4 |
AS |
$31.59 |
$474,968 |
D/D |
(15,000) |
15,000 |
|
- |
|
| Crystal Adam |
Chief Medical Officer |
• – – |
2022-01-04 |
4 |
OE |
$6.49 |
$97,350 |
D/D |
15,000 |
30,000 |
|
- |
|
| Crystal Adam |
Chief Medical Officer |
• – – |
2021-12-22 |
4 |
OE |
$6.49 |
$32,450 |
D/D |
5,000 |
15,000 |
|
- |
|
| Salter Malcolm |
Director |
– • – |
2021-12-17 |
4 |
AS |
$30.25 |
$22,839 |
D/D |
(755) |
10,952 |
|
- |
|
| Fisher Stewart |
Chief Scientific Officer |
• – – |
2021-12-08 |
4 |
OE |
$2.11 |
$73,000 |
D/D |
20,562 |
43,306 |
|
- |
|
| Salter Malcolm |
Director |
– • – |
2021-11-19 |
4 |
AS |
$40.11 |
$30,283 |
D/D |
(755) |
11,707 |
|
- |
|
| Salter Malcolm |
Director |
– • – |
2021-10-15 |
4 |
AS |
$44.94 |
$33,930 |
D/D |
(755) |
12,462 |
|
- |
|
| Crystal Adam |
Chief Medical Officer |
• – – |
2021-10-08 |
4 |
OE |
$6.49 |
$64,900 |
D/D |
10,000 |
10,000 |
|
- |
|
| Dubin Glenn |
Director |
– • – |
2021-10-04 |
4 |
A |
$44.99 |
$6,209 |
D/D |
138 |
295 |
|
- |
|
| Cohen Marc A |
Director |
– • – |
2021-10-04 |
4 |
A |
$44.99 |
$20,740 |
D/D |
461 |
461 |
|
- |
|
166 Records found
|
|
Page 4 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
